EPISODE · Aug 15, 2025 · 40 MIN
Justin Chickles, CEO & Co-Founder of Glycyx Therapeutics
from Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere · host Julio G. Martinez-Clark
Could opioids be silently undermining cancer immunotherapy?This week, Justin Chickles — CEO and co-founder of Glycyx Therapeutics — explains how his team is tackling this overlooked challenge with axelopran, a breakthrough therapy now advancing to Phase 2 trials.From his early career at Johnson & Johnson to leading multiple startups, Justin offers a rare, insider’s perspective on driving biotech innovation from concept to clinic. If you’re interested in cutting-edge oncology, translational science, and biotech entrepreneurship, you won’t want to miss this episode.
What this episode covers
Could opioids be silently undermining cancer immunotherapy? This week, Justin Chickles — CEO and co-founder of Glycyx Therapeutics — explains how his team is tackling this overlooked challenge with axelopran, a breakthrough therapy now advancing to Phase 2 trials. From his early career at Johnson & Johnson to leading multiple startups, Justin offers a rare, insider’s perspective on driving biotech innovation from concept to clinic. If you’re interested in cutting-edge oncology, translat...
NOW PLAYING
Justin Chickles, CEO & Co-Founder of Glycyx Therapeutics
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m